Alcohol on GLP-1 medicines
Quick answer. Expert guidance says alcohol can worsen nausea and reflux on GLP-1 medicines and should be kept low. Separately, an early trial of 48 adults with alcohol use disorder found that low-dose semaglutide reduced craving and drinks per drinking day. No GLP-1 medicine is approved to treat alcohol use disorder, and the Atlas found no trial of safe drinking amounts for people on these medicines.
Two separate questions
There are two questions here that often get mixed up. One is practical: how does drinking mix with the medicine day to day? The other is scientific: do these medicines change how much people want to drink?
Many people on GLP-1 medicines say their interest in alcohol falls. That is an observation from clinics and communities, and researchers are now testing it. It is not the same as saying the medicine makes drinking safe.
What trials show
The best trial so far is a 2025 phase 2 randomized trial in JAMA Psychiatry. It enrolled 48 adults with alcohol use disorder who were not seeking treatment (71% women, average age about 40) and gave them weekly semaglutide at low, rising doses or placebo for 9 weeks. Semaglutide reduced the amount of alcohol people drank in a lab test afterward, and reduced drinks per drinking day and weekly craving. It did not change average drinks per calendar day or the number of drinking days. Smokers in the group also smoked fewer cigarettes. The authors call these initial findings that justify larger trials.
A 2026 review pulled the early evidence together. It reports that large cohort studies showed fewer alcohol-related hospital stays in people on semaglutide than in non-users, and that tirzepatide was linked to lower odds of binge drinking and lower alcohol-screening scores, with the clearest effects in people with obesity or metabolic disease. It also states plainly that no GLP-1 medicine is approved for alcohol use disorder, and that the evidence is limited by small samples, short follow-up, self-reported outcomes and possible confounding from weight loss.
The Atlas did not find a trial that tested how much alcohol is safe for people on these medicines.
What experts say about drinking on the medicine
The 2025 advisory says alcohol may worsen nausea and gastroesophageal reflux on GLP-1 therapy and should be minimized. Its authors add that, in their clinical experience, cravings for high-fat food, sugary food and alcohol fall in many patients, which is an observation and not a trial result.
The advisory also says substance use, including alcohol, should be addressed to get the most from treatment, and that clinicians should educate people about possible interactions and routinely screen for it. It cites the phase 2 trial above as a sign that these medicines may help reduce alcohol use.
The 2023 consensus urges caution in people with a history of pancreatitis or gallbladder disease, and the labels list both as warnings. If you drink heavily or have had pancreas trouble, that is a conversation to have with your prescriber.
What people report
In online communities, many people on GLP-1 medicines say they lost interest in alcohol, drink less, or stopped without trying. The themes people commonly describe are that one drink feels like enough, that alcohol tastes worse, and that a drink can bring on nausea, reflux or a bad hangover. Some people describe feeling the effects faster.
None of this was measured. People who notice a change are more likely to post, and nobody confirms what they actually drank. It is here because the topic is everywhere, not because it shows the medicine affects drinking for you.
Who needs to be careful
- Anyone with a history of pancreatitis or gallbladder disease.
- Anyone with diabetes who uses insulin or a sulfonylurea, who should ask how alcohol and low blood sugar fit together for them.
- Anyone who drinks heavily or has alcohol use disorder, who should talk with a clinician and not treat the medicine as a treatment for it.
- Anyone with reflux or frequent nausea, since the advisory says alcohol can make both worse.
Questions to bring to a clinician or dietitian
- Is any alcohol reasonable for me on this medicine?
- Do my other conditions or medicines change that answer?
- My drinking has changed since I started. Is that something to track or discuss?
- If I struggle with alcohol, what support is available?
What is still unknown
- Whether these medicines reduce drinking in people without alcohol use disorder is not established by trials.
- What amount of alcohol, if any, is low risk on these medicines has not been tested.
- Whether any reduction lasts after stopping is unknown.
- Whether newer medicines such as tirzepatide reduce alcohol use as semaglutide may is based on early observational data.
Related pages
Sources
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society Mozaffarian D, et al. Obes Pillars. 2025;15:100181. PMID 40673264. Funding: Professional societies; several authors report industry relationships. Journal article
- Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial Hendershot CS, et al. JAMA Psychiatry. 2025;82(4):395-405. PMID 39937469. Funding: Not stated in the abstract. Journal article
- Exploring semaglutide for alcohol use disorder: a review of clinical efficacy and neurobiological mechanisms Nittur A, Belzar A, Rai C. Addict Behav. 2026;185:108878. PMID 42880142. Funding: Not stated in the abstract. Journal article
- Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus Gorgojo-Martínez JJ, et al. J Clin Med. 2023;12(1):145. PMID 36614945. Funding: Not stated in the abstract. Journal article
- Wegovy (semaglutide) injection and tablets: prescribing information Novo Nordisk, on DailyMed (U.S. National Library of Medicine). Label version 6/2026. One label covers both the injection and the tablets. Official FDA label on DailyMed
- Zepbound (tirzepatide) injection: prescribing information Eli Lilly and Company, on DailyMed (U.S. National Library of Medicine). Label version 8/2026. Official FDA label on DailyMed